From: Heart sparing radiotherapy in breast cancer: the importance of baseline cardiac risks
Non-diabetic patients (n = 200) | Diabetic patients (n = 10) | ||||
---|---|---|---|---|---|
Age at diagnosis (years) | < 40 | 16 | (8.0%) | 0 | |
40–49 | 32 | (16.0%) | 2 | (20%) | |
50–59 | 73 | (36.5%) | 2 | (20%) | |
60–69 | 45 | (22.5%) | 5 | (50%) | |
70–79 | 33 | (16.5%) | 1 | (10%) | |
≥80 | 1 | (0.5%) | 0 | ||
Mean | 57 | 60 | |||
Smoking habit | positive | 26 | (13.0%) | 2 | (20%) |
negative | 174 | (87.0%) | 8 | (80%) | |
Family history | positive | 27 | (13.5%) | 1 | (10%) |
negative | 173 | (86.5%) | 9 | (90%) | |
LDL (mg/dL) | < 100 | 37 | (18.5%) | 3 | (30%) |
100–149 | 111 | (55.5%) | 6 | (60%) | |
150–199 | 43 | (21.5%) | 0 | ||
> 200 | 9 | (4.5%) | 1 | (10%) | |
Mean | 130 | 115 | |||
HDL (mg/dL) | < 50 | 20 | (10%) | 4 | (40%) |
50–99 | 169 | (84.5%) | 6 | (60%) | |
> 100 | 11 | (5.5%) | 0 | ||
Mean | 69 | 57 | |||
Triglycerides (mg/dL) | < 50 | 5 | (2.5%) | 1 | (10%) |
50–99 | 84 | (42.0%) | 2 | (20%) | |
100–149 | 62 | (31.0%) | 1 | (10%) | |
150–199 | 23 | (11.5%) | 1 | (10%) | |
200–249 | 19 | (9.5%) | 3 | (30%) | |
> 250 | 7 | (3.5%) | 2 | (20%) | |
Mean | 122 | 171 | |||
Total Cholesterol (mg/dL) | 100–149 | 3 | (1.5%) | 1 | (10%) |
150–199 | 54 | (27.0%) | 5 | (50%) | |
200–249 | 97 | (48.5%) | 3 | (30%) | |
250–299 | 34 | (17.0%) | 1 | (10%) | |
> 300 | 12 | (6.0%) | 0 | ||
Mean | 223 | 203 | |||
(hs) CRP (mg/dL) | < 0.1 | 65 | (32.5%) | 2 | (20%) |
0.1–0.5 | 115 | (57.5%) | 6 | (60%) | |
> 0.5 | 20 | (10.0%) | 2 | (20%) | |
Mean | 0.23 | 0.55 | |||
Mean heart dose DIBH (Gy) | < 1.0 | 37 | (18.5%) | 0 | |
1.0–1.9 | 142 | (71.0%) | 6 | (60%) | |
2.0–4.9 | 20 | (10.0%) | 4 | (40%) | |
> 5.0 | 1 | (0.5%) | 0 | ||
Mean | 1.42 | 1.85 | |||
95% CI | 1.34–1.50 | 1.47–2.24 | |||
Mean heart dose FB (Gy) | < 1.0 | 10 | (5.0%) | 0 | |
1.0–1.9 | 87 | (43.5%) | 1 | (10%) | |
2.0–4.9 | 97 | (48.5%) | 9 | (90%) | |
> 5.0 | 6 | (3.0%) | 0 | ||
Mean | 2.33 | 2.86 | |||
95% CI | 2.17–2.49 | 2.26–3.47 |